BioConnect AG advised financing round for 20/10 Perfect Vision AG
CFP BioConnect AG acted as exclusive financial advisor to Heidelberg – based medical technology company 20/10 Perfect Vision AG (“20/10 PerfectVision”) in a EUR 7.5 million (USD 10 million) financing round.
HealthCap (Stockholm) acted as lead investor and was joined by existing investors NBGI Ventures (London), IBG Beteiligungsgesellschaft mbH, Sachsen - Anhalt (Magdeburg), Innoven Partennaires (Paris) and Entrepreneurs Fund (London).
The funding proceeds will enable the company to accelerate the development of presbyopia correcting treatments by using its FEMTEC® femtosecond laser workstation. The system offers eye surgeons a broad variety of innovative procedures including refractive laser surgery applications.
Recently, 20/10 Perfect Vision AG announced that it has entered into a joint venture with Bausch & Lomb, the global eye health company, to combine the refractive eye surgery assets of both businesses.
Corporate Finance Partners acted as an exclusive adviser to 20/10 Perfect Vision AG.
«backHealthCap (Stockholm) acted as lead investor and was joined by existing investors NBGI Ventures (London), IBG Beteiligungsgesellschaft mbH, Sachsen - Anhalt (Magdeburg), Innoven Partennaires (Paris) and Entrepreneurs Fund (London).
The funding proceeds will enable the company to accelerate the development of presbyopia correcting treatments by using its FEMTEC® femtosecond laser workstation. The system offers eye surgeons a broad variety of innovative procedures including refractive laser surgery applications.
Recently, 20/10 Perfect Vision AG announced that it has entered into a joint venture with Bausch & Lomb, the global eye health company, to combine the refractive eye surgery assets of both businesses.
Corporate Finance Partners acted as an exclusive adviser to 20/10 Perfect Vision AG.
